| 000 | 01644 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250513150348.0 | ||
| 264 | 0 | _c19980826 | |
| 008 | 199808s 0 0 eng d | ||
| 022 | _a0021-9738 | ||
| 024 | 7 |
_a10.1172/JCI3741 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBlazar, B R | |
| 245 | 0 | 0 |
_aCD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. _h[electronic resource] |
| 260 |
_bThe Journal of clinical investigation _cAug 1998 |
||
| 300 |
_a473-82 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _ximmunology |
| 650 | 0 | 4 |
_aCD4-Positive T-Lymphocytes _xdrug effects |
| 650 | 0 | 4 |
_aCD40 Antigens _ximmunology |
| 650 | 0 | 4 | _aCD40 Ligand |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aGraft vs Host Disease _ximmunology |
| 650 | 0 | 4 | _aImmunosuppression Therapy |
| 650 | 0 | 4 |
_aInterleukin-2 _xpharmacology |
| 650 | 0 | 4 |
_aIsoantigens _ximmunology |
| 650 | 0 | 4 | _aLymphocyte Culture Test, Mixed |
| 650 | 0 | 4 |
_aMembrane Glycoproteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred BALB C |
| 650 | 0 | 4 | _aMice, Inbred C57BL |
| 650 | 0 | 4 | _aMice, SCID |
| 650 | 0 | 4 | _aSpecific Pathogen-Free Organisms |
| 700 | 1 | _aTaylor, P A | |
| 700 | 1 | _aNoelle, R J | |
| 700 | 1 | _aVallera, D A | |
| 773 | 0 |
_tThe Journal of clinical investigation _gvol. 102 _gno. 3 _gp. 473-82 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1172/JCI3741 _zAvailable from publisher's website |
| 999 |
_c9656752 _d9656752 |
||